HomeIndustriesMerck Raises Full-Year Forecast After Beating Q2 Estimate

Merck Raises Full-Year Forecast After Beating Q2 Estimate

Merck & Co decided to raise its full-year revenue forecast on Tuesday after posting better-than-expected financial results for the second quarter. Shares in the company rose by 1% in premarket trading on Tuesday morning.

Sales for Q2 were $15 billion, up from $14.6 billion during the same quarter a year ago. This comes despite a sharp decline in demand for the company’s COVID-19 therapeutic Lagevrio.

Keytruda drug sales for the quarter were $6.3 billion, outpacing the $5.9 billion forecasted by analysts. Sales for the cancer prevention drug Gardasil have surged by 47% to $2.5 billion. In contrast, sales of Lagevrio plummeted from $1.2 billion a year ago to $200 million today.

Despite positive revenue data, the company reported a quarterly adjusted loss of $5.2 billion, or $2.06 a share. This is primarily because of the $10.2 billion forked out by Merck to acquire Prometheus Biosciences. Even with this major expense, the company’s loss still beat analysts’ expectations of a $2.18 loss per share.

Merck now expects full-year sales in the range of $58.6 to $59.6 billion; up from its previous forecast of $57.7 billion to $58.9 billion.

Zoom Tops Estimates, Raises Full-Year Forecast

Zoom Video Communications reported its earnings for the first quarter of 2024 on Monday and topped the estimates of Wall Street analysts. The communications...

Reddit Stock Jumps on the Back of Open AI Partnership

Social media platform Reddit announced earlier this week that it is partnering up with artificial intelligence start-up Open AI to improve the experience of...

Warren Buffett’s Berkshire Hathaway Reveals Its Secret Stock

For the past three regulatory filings, Warren Buffett’s Berkshire Hathaway has been keeping one of its stock holdings confidential. Now, the conglomerate revealed that...